Company / Operating Cash Flow
Dyne Therapeutics, Inc. Operating Cash Flow History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$292.4M
FY2024
5-year range
-$292.4M / -$46.5M
FY2020-FY2024
Trend
-55.4%
vs FY2023
Sector context
#189 of 214
Health Care
What the data says
Dyne Therapeutics, Inc.'s operating cash flow of -$292M is lower than 88% of companies in the Health Care sector (FY2024). Operating Cash Flow has declined for 5 consecutive years, from -$12M in FY2019 to -$292M in FY2024.
Based on SEC 10-K filings.
-$292M in FY2024.
Declined from -$154M to -$292M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 214This company -$292.4M Sector average $663.6M
▼
-144.1% below sector average
Key checks
Key Insights
- Dyne Therapeutics, Inc.'s operating cash flow has declined for 5 consecutive years.
- In FY2024, operating cash flow decreased 55.4% year-over-year.
- Ranks #189 out of 214 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 3.40 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$292.4M | -55.4% |
| FY2023 | -$188.2M | -22.5% |
| FY2022 | -$153.6M | -28.5% |
| FY2021 | -$119.6M | -157.1% |
| FY2020 | -$46.5M | -293.0% |
| FY2019 | -$11.8M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026